LAKE
FOREST, Calif., Oct. 10,
2023 /PRNewswire/ -- STAAR Surgical Company
(NASDAQ: STAA), a leading developer, manufacturer and marketer of
implantable lenses for the eye, is proud to announce a partnership
with renowned actor and comedian, Jimmy O.
Yang. This partnership brings together EVO Implantable
Collamer® Lenses (EVO ICL) for nearsightedness and
astigmatism and the voice of Jimmy O.
Yang. The EVO ICL vision correction procedure has been a
life-changing experience for him.
Jimmy O. Yang, who is widely
recognized for his stand-up comedy and roles in hit TV series and
movies, including "Silicon Valley", "Crazy Rich Asians", and the
upcoming "Interior Chinatown" on Hulu, has been thrilled with his
results after receiving EVO ICL lenses. He shares his own
experience, stating, "EVO ICL has been a game-changer for me. After
learning about this cutting-edge technology, choosing EVO ICL was
an easy decision for me. I wish I would have done it earlier. It's
a minimally invasive procedure, the lenses are removable by a
doctor if ever needed in the future, and it gives me clear vision
without causing dry eye syndrome.1,2 This eliminates the
hassle of having to wear glasses or contacts when I'm going on the
road for standup or crafting a new role for a show. I'm excited to
partner with EVO ICL to raise awareness about this remarkable and
simple procedure that has the potential to transform many lives,
like it did for me."
"The popularity of the EVO ICL procedure has grown consistently
over the years," says Dr. Paul C.
Lee – eye surgeon and Founder, CCRS, Los Angeles – who performed the procedure on
Mr. Yang and has been at the forefront of new developments in
vision correction options. "Like with Jimmy
O. Yang, I am seeing an increasing number of patients who
qualify for both EVO ICL and laser vision correction opting for the
lens-based surgery. This trend reflects the public's growing
awareness of ICL surgery's proven long-term benefits and how the
EVO ICL lens works in harmony with the natural function of the eye.
I am personally witnessing this phenomenon as I see patients in
whom I did ICL more than a decade ago, and I am incredibly excited
about the potential it holds for revolutionizing vision
correction."
STAAR Surgical is equally enthusiastic about this collaboration.
Tom Frinzi, CEO of STAAR Surgical,
states, "We are happy to have Jimmy O.
Yang join us in our mission to build EVO Brand Awareness for
this life-changing myopia vision solution. His endorsement and
passion for EVO ICL will undoubtedly inspire many potential
patients to explore EVO and empower them to correct their
vision."
EVO ICL represents a significant advancement in vision
correction technology as it works in harmony with the natural eye.
The FDA-approved EVO ICL lenses are successful in correcting both
myopia and myopia with astigmatism. The EVO procedure implants a
proprietary, biocompatible Collamer® lens into the eye
between the iris and natural lens, taking only 20–30 minutes. Most
patients see immediate improvement, EVO ICL corrects vision without
the need to remove corneal tissue and does not cause dry eye
syndrome.1,2
EVO ICL lenses have been approved, marketed, and successfully
implanted by ophthalmologists throughout North America, Europe, Asia,
and the rest of the world. According to a patient survey, 99.4% of
patients would have the EVO ICL procedure again.3 Over
2,500,000 ICLs have been distributed globally.
For more information about EVO Implantable Collamer®
Lenses, please visit https://evoicl.com.
References:
- Ganesh S, Brar S, Pawar A. Matched population comparison of
visual outcomes and patient satisfaction between 3 modalities for
the correction of low to moderate myopic astigmatism. Clin
Ophthalmol. 2017;11:1253-1263.
- Naves J.S, Carracedo G, Cacho-Babillo I, Diadenosine nucleotid
measurements as dry-eye score in patients after LASIK and ICL
surgery. Presented at American Society of Cataract and Refractive
Surgery (ASCRS) 2012.
- Packer M. The Implantable Collamer Lens with a central port:
review of the literature. Clinical Ophthalmology 2018: 12:
2427–2438.
About STAAR Surgical
STAAR, which has been dedicated
solely to ophthalmic surgery for over 40 years, designs, develops,
manufactures, and markets implantable lenses for the eye. These
lenses are intended to provide visual freedom for patients,
lessening or eliminating the reliance on glasses or contact lenses.
All these lenses are foldable, which permits the surgeon to insert
them through a small incision. STAAR's lens used in refractive
surgery is called an Implantable Collamer® Lens or
"ICL," which includes the EVO ICL™ product line. More than
2,000,000 ICLs have been sold to date and STAAR markets these
lenses in over 75 countries. To learn more about the ICL go to:
www.evoicl.com. Headquartered in Lake
Forest, CA, the company operates manufacturing and packaging
facilities in Aliso Viejo, CA,
Monrovia, CA and Nidau,
Switzerland. For more information,
please visit the Company's website at www.staar.com.
Safe Harbor
All statements that are not statements of
historical fact are forward-looking statements, including
statements about any of the following: product safety,
effectiveness, or performance for any particular patient, and any
statements of assumptions underlying any of the foregoing.
Important factors that could cause actual results to differ
materially from those indicated by such forward-looking statements
include risk factors set forth in the Company's Annual Report on
Form 10-K for the year ended December 30,
2022 under the caption "Risk Factors," which is on file with
the Securities and Exchange Commission and available in the
"Investor Information" section of the company's website under the
heading "SEC Filings." We disclaim any intention or obligation to
update or revise any forward-looking statements due to new
information or events. These statements are based on expectations
and assumptions as of the date of this press release and are
subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those described in the
forward-looking statements.
Important Safety Information for EVO ICL
The EVO ICL
lens is intended to correct/reduce nearsightedness between -3.0 D
up to -20.0 D and treat astigmatism from 1.0 D to 4.0 D. If you
have nearsightedness within these ranges, EVO ICL surgery may
improve your distance vision without eyeglasses or contact lenses.
Because the EVO ICL corrects for distance vision, it does not
eliminate the need for reading glasses, you may require them at
some point, even if you have never worn them before. Since
implantation of the EVO ICL is a surgical procedure, before
considering EVO ICL surgery you should have a complete eye
examination and talk with your eye care professional about EVO ICL
surgery, especially the potential benefits, risks, and
complications. You should discuss the time needed for healing after
surgery. Complications, although rare, may include need for
additional surgical procedures, inflammation, loss of cells from
the back surface of the cornea, increase in eye pressure, and
cataracts. You should NOT have EVO ICL surgery if your doctor
determines that 1) the shape of your eye is not appropriate, 2) you
do not meet the minimum endothelial cell density for your age at
the time of implantation, 3) you have moderate to severe glaucoma,
4) your vision is not stable; or 5) if you are pregnant or
nursing.
For additional information with potential benefits, risks, and
complications please visit evoicl.com.
Media Contact
5W Public Relations
EVO@5wpr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/jimmy-o-yang-partners-with-staar-surgical-to-shine-a-light-on-their-vision-correction-lens-evo-icl-301952455.html
SOURCE STAAR Surgical Company